# US 2023/0058176 A1 · Switchable cas9 nucleases and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058176 A1
- Document ID: US20230058176A1
- Status: Published application
- Kind: A1
- Application number: 17/688,416
- Filed: 2022-03-07
- Published: 2023-02-23
- Earliest claimed: 2013-09-06
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: David R. Liu; Johnny Hao Hu
- Web page: https://patentgrep.com/patent/US20230058176A1

## CPC

- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/907: {in mammalian cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 15/01: Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/10: Type of nucleic acid
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/16: Aptamers
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2310/53: partially self-complementary or closed
- C12N 2320/53: reducing unwanted side-effects
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and hence cleavage activity of RNA-programmable endonucleases. Some aspects of this disclosure provide mRNA-sensing gRNAs that modulate the activity of RNA-programmable endonucleases based on the presence or absence of a target mRNA. Some aspects of this disclosure provide gRNAs that modulate the activity of an RNA-programmable endonuclease based on the presence or absence of an extended DNA (xDNA).

## Claims

### Claim at position 1

1-113. (canceled)

### Claim 114

A switchable single-guide RNA (sgRNA), comprising an sgRNA backbone sequence; an RNA aptamer; and a guide sequence that is complementary to a DNA target site.

### Claim 115 (depends on 114)

The sgRNA of claim 114, wherein the RNA aptamer comprises a riboswitch.

### Claim 116 (depends on 115)

The sgRNA of claim 115, wherein the riboswitch is a theophylline riboswitch.

### Claim 117 (depends on 114)

The sgRNA of claim 114, wherein the RNA aptamer is located at the 5′ end of the sgRNA.

### Claim 118 (depends on 115)

The sgRNA of claim 115, wherein the riboswitch is selected from the group consisting of: theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch, an S-adenosyl methionine (SAM) riboswitch, an SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, and a pre-queosine1 (PreQ1) riboswitch.

### Claim 119 (depends on 114)

The sgRNA of claim 114, wherein the sgRNA does not to bind to the DNA target site in the absence of a ligand bound to the RNA aptamer.

### Claim 120 (depends on 119)

The sgRNA of claim 119, wherein the ligand is selected from the group consisting of small molecules, metabolites, peptides, and nucleic acids.

### Claim 121 (depends on 119)

The sgRNA of claim 119, wherein the ligand is theophylline.

### Claim 122 (depends on 114)

A complex comprising a Cas9 protein and the switchable sgRNA of claim 114.

### Claim 123 (depends on 122)

The complex of claim 122, wherein the sgRNA:Cas9 complex binds the DNA target site in the presence of a ligand.

### Claim 124 (depends on 114)

A polynucleotide encoding the switchable sgRNA of claim 114.

### Claim 125 (depends on 124)

A vector comprising the polynucleotide of claim 124.

### Claim 126 (depends on 114)

A complex comprising the switchable sgRNA of claim 114, a ligand, and a Cas9 protein.

### Claim 127 (depends on 126)

The complex of claim 126, wherein the sgRNA:ligand:Cas9 complex binds the DNA target site.

### Claim 128 (depends on 114)

An isolated cell comprising the switchable sgRNA of claim 114.

### Claim 129 (depends on 128)

The isolated cell of claim 128, wherein the cell expresses a Cas9 protein.

### Claim 130 (depends on 114)

A method for site-specific DNA cleavage, comprising:
contacting a target DNA with a complex comprising:
(i) the switchable sgRNA of claim 114,
wherein the switchable sgRNA comprises a sequence that binds to a portion of the target DNA,
(ii) a ligand bound to the RNA aptamer of the switchable sgRNA, and
(iii) a Cas9 protein, under conditions in which a Cas9 protein cleaves at least one strand of the target DNA.

### Claim 131 (depends on 130)

The method of claim 130, wherein the target DNA is in a cell.

### Claim 132 (depends on 131)

The method of claim 131, wherein the cell is a eukaryotic cell.

### Claim 133 (depends on 132)

The method of claim 132, wherein the cell is in an individual.

### Claim 134 (depends on 133)

The method of claim 133, wherein the individual is a human.

### Claim 135 (depends on 114)

A method for inducing site-specific DNA cleavage in a cell comprising:
(a) contacting a cell or expressing within a cell the switchable sgRNA of claim 114,
wherein the switchable sgRNA comprises a sequence capable of binding to a target DNA;
(b) contacting the cell or expressing within the cell a Cas9 protein; and
(c) contacting the cell with a ligand that binds the RNA aptamer of the switchable sgRNA,
resulting in the formation of a switchable sgRNA:ligand:Cas9 complex that cleaves at least one strand of the target DNA.

### Claim 136 (depends on 114)

A method for inducing site-specific DNA cleavage in a cell comprising:
(a) contacting the cell with a complex comprising a Cas9 protein and the switchable sgRNA of claim 114, wherein the switchable sgRNA comprises a sequence capable of binding to a target DNA sequence, and
(b) contacting the cell with a ligand that binds the RNA aptamer of the switchable sgRNA, resulting in the formation of a switchable sgRNA:ligand:Cas9 complex that cleaves at least one strand the target DNA sequence.

### Claim 137 (depends on 136)

The method of claim 136, wherein steps (a) and (b) are performed simultaneously or sequentially in any order.
